Leadership

Evozyne CEO Marc Yoskowitz is a veteran biopharma executive known for leading public and private companies through transformative periods of growth.

Prior to joining Evozyne, Yoskowitz was chief strategy officer and executive vice president of life sciences at Tempus AI. He has held executive leadership positions with Pfizer, Hospira and McKinsey & Company.

Yoskowitz has a lengthy track record of business building, P&L leadership, creative deal-making and strategic planning, with a deep reservoir of industry relationships. Over the course of his career, he has served as an operating executive, board member and advisor, leading global and domestic work across all facets of the biopharmaceutical value chain.He holds a JD from Columbia Law School.

Arjun Rallapalli leads Evozyne’s operations and execution strategy, translating the company’s platform capabilities into scalable products, partnerships, and commercial impact. He oversees cross-functional execution across R&D, business operations, and corporate strategy to drive growth and organizational performance. Before Evozyne, Rallapalli was a manager at McKinsey & Company, where he led strategy engagements across different sectors. He began his career at GE Healthcare before obtaining a PhD in electrical engineering at Duke University where he explored the possibility of creating photonic logic devices using DNA and organic molecules.

Uri Herzberg has extensive expertise in drug discovery with companies including Johnson & Johnson, Celgene, Cabaletta Bio, Celularity and Fresh Tracks Therapeutics. His expertise encompasses preclinical development, translational research, regulatory strategy, early clinical trial design target identification and indication selection. He holds a doctorate in veterinary medicine, a PhD in veterinary biology and neuroimmunology and an MBA in pharmaceutical development.

Stephen Wanaski, Ph.D., is senior vice president of research and exploratory development at Evozyne, overseeing basic science, pharmacology and toxicology, clinical pharmacology, and scientific due diligence.

Dr. Wanaski is an experienced drug development leader with a track record in orphan drug development of small and large molecules from discovery through late-stage clinical studies and FDA approval.   He previously served as vice president of research and exploratory development at Castle Creek Pharmaceuticals and Marathon Pharmaceuticals, where he played a key role in the approval of a Duchenne muscular dystrophy therapy.

Earlier, Dr. Wanaski held senior R&D roles at NeuroTherapeutics Pharma and Ovation Pharmaceuticals, supporting multiple first-cycle NDA approvals. He began his career at oncology-focused NeoPharm and holds a bachelor’s degree from the University of Notre Dame and a Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign.